Design, synthesis and evaluation of 2-amino-imidazol-4-one derivatives as potent β-site amyloid precursor protein cleaving enzyme 1 (BACE-1) inhibitors
Authors:
- 1 December 2019
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 29 (24) , 126772
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Jiangsu Province
- National Natural Science Foundation of China
This publication has 18 references indexed in Scilit:
- BACE inhibitors in clinical development for the treatment of Alzheimer’s diseaseExpert Review of Neurotherapeutics, 2018
- BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid Aβ PeptidesThe Journal of Clinical Pharmacology, 2017
- Novel multitarget-directed tacrine derivatives as potential candidates for the treatment of Alzheimer’s diseaseJournal of Enzyme Inhibition and Medicinal Chemistry, 2017
- The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patientsScience Translational Medicine, 2016
- Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ‐54861911, a potent oral BACE inhibitorAlzheimer's & Dementia: Translational Research & Clinical Interventions, 2016
- Alzheimer's Association International Conference on Alzheimer's Disease 2015 (AAIC 2015) (July 18-23, 2015 - Washington, D.C., USA)Drugs of Today, 2015
- The β-secretase enzyme BACE1 as a therapeutic target for Alzheimer's diseaseAlzheimer's Research & Therapy, 2011
- Alzheimer's diseaseThe Lancet, 2006
- Copper, iron and zinc in Alzheimer's disease senile plaquesJournal of the Neurological Sciences, 1998
- Alzheimer's Disease: The Amyloid Cascade HypothesisScience, 1992